tiprankstipranks
Lucid Diagnostics (LUCD)
NASDAQ:LUCD
US Market
Holding LUCD?
Track your performance easily

Lucid Diagnostics (LUCD) Earnings Date & Reports

377 Followers

Earnings Data

Report Date
Mar 31, 2025
TBA Not Confirmed
Period Ending
2024 (Q4)
Consensus EPS Forecast
-$0.17
Last Year’s EPS
-$1.33
Same Quarter Last Year
Based on 6 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Nov 13, 2024
|
% Change Since: -21.90%
|
Next Earnings Date:Mar 31, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook with record revenue growth, strategic expansions, and new partnerships poised to drive future performance. Although there were challenges such as a sequential decline in test volume and a high burn rate, the overall advancements and future potential outweigh these concerns.
Company Guidance
During the Lucid Diagnostics Q3 2024 earnings call, the company reported a revenue of $1.2 million, marking a 20% increase quarter-over-quarter and a 50% increase year-over-year. The test volume for the third quarter was 2,787, with projections showing a record test volume in October. Lucid Diagnostics is focusing on its EsoGuard product, with a test sensitivity of 96% for cancer detection and 85% for pre-cancerous conditions. The company is working towards Medicare coverage, leveraging a robust clinical evidence base, and has expanded initiatives in concierge medicine and employer markets. Lucid's target population is approximately 30 million at-risk patients, with a total addressable market estimated at $60 billion. The company reported a cash balance of $14.5 million as of September 30, 2024, and a quarterly burn rate of $10.4 million. The ongoing efforts to secure reimbursement and direct contracting are aimed at enhancing revenue growth and financial stability.
Record Quarterly Revenue Growth
Lucid Diagnostics achieved a record quarterly revenue of $1.2 million, marking a 20% increase quarter-on-quarter and a 50% increase compared to the previous year's third quarter.
Expansion of Clinical Evidence Base
The EsoGuard BE-1 clinical validation study was accepted for peer-reviewed publication, completing the evidence package necessary for Medicare coverage submission.
Strong Start to Fourth Quarter
October marked a record test volume month, setting a positive tone for the fourth quarter.
Strategic Initiatives and Partnerships
Lucid expanded its direct contracting initiative and is focusing on new revenue-generating programs, including partnerships with concierge medicine and employer markets.
Robust Pipeline and Test Volume Growth
The company has tested over 7,000 firefighters with EsoGuard and is seeing robust pipeline development for fully contracted CYFT events.
---

Lucid Diagnostics (LUCD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

LUCD Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 31, 20252024 (Q4)
-0.17 / -
-1.33
Nov 13, 20242024 (Q3)
-0.21 / -0.20
-0.229.09% (+0.02)
Aug 12, 20242024 (Q2)
-0.20 / -0.20
-0.2313.04% (+0.03)
May 13, 20242024 (Q1)
-0.24 / -0.99
-0.24-312.50% (-0.75)
Mar 25, 20242023 (Q4)
-0.23 / -1.33
-0.33-303.03% (-1.00)
Nov 13, 20232023 (Q3)
-0.24 / -0.22
-0.2821.43% (+0.06)
Aug 14, 20232023 (Q2)
-0.28 / -0.23
-0.4143.90% (+0.18)
May 15, 20232023 (Q1)
-0.33 / -0.24
-0.23-4.35% (>-0.01)
Mar 13, 20232022 (Q4)
-0.33 / -0.33
-0.22-50.00% (-0.11)
Nov 14, 20222022 (Q3)
-0.35 / -0.28
-0.4942.86% (+0.21)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

LUCD Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 13, 2024$1.00$1.05+5.00%
Aug 12, 2024$0.79$0.84+6.33%
May 13, 2024$0.94$0.95+1.06%
Mar 25, 2024$1.06$0.99-6.60%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Lucid Diagnostics (LUCD) report earnings?
Lucid Diagnostics (LUCD) is schdueled to report earning on Mar 31, 2025, TBA Not Confirmed.
    What is Lucid Diagnostics (LUCD) earnings time?
    Lucid Diagnostics (LUCD) earnings time is at Mar 31, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is LUCD EPS forecast?
          LUCD EPS forecast for the fiscal quarter 2024 (Q4) is -$0.17.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis